SMMT
NASDAQ HealthcareSummit Therapeutics Inc. - Common Stock
Biotechnology
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
�� 市场数据
| 价格 | $25.15 |
|---|---|
| 成交量 | 4,876,533 |
| 市值 | 19.50B |
| 贝塔系数 | -1.370 |
| RSI（14日） | 89.5 超买 |
| 200日均线 | $19.83 |
| 50日均线 | $16.95 |
| 52周最高 | $36.91 |
| 52周最低 | $13.83 |
| Forward P/E | -21.32 |
| Price / Book | 29.59 |
🎯 投资策略评分
SMMT 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (92/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🔪 Falling Knife (8/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 SMMT in your text
粘贴任何文章、记录或帖子 — 工具将提取 SMMT 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.